Keefe, Bruyette & Woods Reiterates Ventas Outperform (VTR)

Keefe, Bruyette & Woods reiterated its Ventas VTR Outperform rating in a research report published today. In the report, Keefe, Bruyette & Woods states, "Following VTR's 4Q results and conf call our investment outlook remains largely unchanged. We continue to view Ventas as an attractive opportunity within the healthcare REIT sector given outsized growth potential, low cost of capital, and reasonable valuation at 17.5x our 2012 AFFO estimate of $3.14." Shares of Ventas were trading at $56.17 at the time of posting, up 1.13% from Thursday's market close.